Forbion related stories
All articles and analysis
- Euro Venture Takes a Tumble in 2011
Optimism is still high in 2012, as a number of portfolio companies stand ready to exit
- Oxyrane Adds $26.5M
Oxyrane UK Ltd., a biopharmaceutical company based in The Netherlands, has closed on $26.5 million in a equity round of funding. Investors include Forbion Capital Partners, Morningside Groups and New Science Ventures. Sander Slootweg of Forbion and Gerald Chan of Morningside Group have joined the company’s board. Oxyrane is developing enzyme replacement therapies to treat rare inheritied diseases.
- Amakem Seals $25.3M Series A
Forbion Capital Partners has led an 18 million euro ($25.3 million) Series A round for Belgium-based Amakem NV. Crédit Agricole Private Equity, Vesalius BioCapital, as well as the existing investors LRM, PMV and Life Sciences Research Partners also contributed to the round. Amakem will use the money to expand its ophthalmology drug development portfolio, the company said.
- Cellnovo Raises $48.4M Series B
London-based Cellnovo, which develops a mobile diabetes management system, has raised £30 million ($48.4 million) in a Series B financing round led by Paris-based Edmond de Rothschild Investment Partners. Forbion Capital Partners, Auriga Partners, NBGI Ventures and Credit Agricole Private Equity also participated, as did Series A investors Advent Venture Partners, HealthCare Ventures and NESTA.